Neumora Therapeutics Inc (NMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.31-2.96%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Neumora aims to fund operations into Q3 2027. It plans to finish NMRA-511 dose study by Q4 2026. The company targets starting a Phase 2b study for NMRA-511 by end of 2026. Recent earnings beats show some progress.
The company is loss-making and fragile. Workforce cuts and new debt raise concerns. Earnings remain negative and revenue is minimal. Progress on drug studies is uncertain.
The market reflects a sharp recent selloff and elevated risk. There is no clear consensus on revenue growth or fair value. Our view is cautious given the weak financials and mixed progress.
Breaks if: Cash runway falls short of Q3 2027
Breaks if: Dose study not completed by Q4 2026
Breaks if: Phase 2b study not started by end of 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. NMRA is currently navigating through a challenging phase with low confidence in its earnings quality and high risk, while also benefiting from a favorable sector backdrop.
The market appears to be pricing in a cautious outlook given NMRA's loss-making status and the potential for negative guidance cuts. Expectations may be tempered due to the company's recent financial performance and the broader economic conditions affecting cyclical names.
Management has indicated a commitment to fund operations into Q3 2027, despite a decline in cash reserves. The advancement of clinical programs for Alzheimer's and obesity shows some positive momentum, but overall financial performance remains neutral.
Key factors include the potential for negative guidance cuts and the impact of economic indicators like the jobs report. Additionally, the performance of sector leaders could influence NMRA's trajectory positively if they continue to exceed expectations.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The next year or two will be critical for NMRA as it balances operational challenges with sector dynamics. Not investment advice.